Edwards Lifesciences (EW) Current Assets (2009 - 2026)

Edwards Lifesciences has reported Current Assets for 18 years, with the latest figure at $6.8 billion in Q2 2026.

• On a quarterly basis, Current Assets rose 3.67% year-over-year to $6.8 billion in Q2 2026; TTM through Jun 2026 was $6.8 billion, a 3.67% increase from a year earlier, with the FY2025 full-year figure at $6.7 billion, up 7.22% from the prior year.
• Current Assets was $6.8 billion for Q2 2026 at Edwards Lifesciences, up from $6.2 billion in the prior quarter.
• The five-year high for Current Assets was $6.8 billion in Q2 2026, with the low at $3.1 billion in Q4 2022.
• Average Current Assets over 5 years is $4.9 billion, with a median of $4.3 billion recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Current Assets jumped 65.4% in 2024, then decreased 5.48% in 2025.
• Over 5 years, Current Assets stood at $3.1 billion in 2022, then surged by 30.36% to $4.0 billion in 2023, then surged by 55.74% to $6.3 billion in 2024, then grew by 7.22% to $6.7 billion in 2025, then increased by 1.19% to $6.8 billion in 2026.
• The last three Current Assets figures came in at $6.8 billion (Q2 2026), $6.2 billion (Q1 2026), and $6.7 billion (Q4 2025), per Business Quant data.